Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
335
mi
from 43215
Milwaukee, WI
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
1636
mi
from 43215
Federal,
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
1636
mi
from 43215
Federal,
Click here to add this to my saved trials
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
450
mi
from 43215
Egg Harbor Township, NJ
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
450
mi
from 43215
Egg Harbor Township, NJ
Click here to add this to my saved trials
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
306
mi
from 43215
Winston-Salem, NC
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Polyp Prevention Trial
Polyp Prevention Trial
Status: Enrolling
Updated:  12/31/1969
322
mi
from 43215
Bethesda, MD
Polyp Prevention Trial
Polyp Prevention Trial
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers
Status: Enrolling
Updated:  12/31/1969
995
mi
from 43215
Houston, TX
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
1167
mi
from 43215
Lakewood, CO
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1167
mi
from 43215
Lakewood, CO
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
1164
mi
from 43215
Littleton, CO
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1164
mi
from 43215
Littleton, CO
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
810
mi
from 43215
New Port Richey, FL
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
810
mi
from 43215
New Port Richey, FL
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
791
mi
from 43215
Winter Park, FL
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
791
mi
from 43215
Winter Park, FL
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
274
mi
from 43215
Chicago, IL
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
188
mi
from 43215
Louisville, KY
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
797
mi
from 43215
Metairie, LA
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
797
mi
from 43215
Metairie, LA
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
721
mi
from 43215
Monroe, LA
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
721
mi
from 43215
Monroe, LA
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
354
mi
from 43215
Annapolis, MD
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
354
mi
from 43215
Annapolis, MD
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
342
mi
from 43215
Towson, MD
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
342
mi
from 43215
Towson, MD
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
186
mi
from 43215
Chesterfield, MI
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
186
mi
from 43215
Chesterfield, MI
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
559
mi
from 43215
Rochester, MN
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
371
mi
from 43215
Raleigh, NC
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
98
mi
from 43215
Cincinnati, OH
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
127
mi
from 43215
Cleveland, OH
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
353
mi
from 43215
Lancaster, PA
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
353
mi
from 43215
Lancaster, PA
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
501
mi
from 43215
Germantown, TN
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
501
mi
from 43215
Germantown, TN
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
422
mi
from 43215
Norfolk, VA
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
2005
mi
from 43215
Seattle, WA
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated:  12/31/1969
15
9462
mi
from 43215
Concord,
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Status: Enrolling
Updated: 12/31/1969
15
9462
mi
from 43215
Concord,
Click here to add this to my saved trials
Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates
Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates
Status: Enrolling
Updated:  12/31/1969
166
mi
from 43215
Indianapolis, IN
Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates
Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates
Status: Enrolling
Updated: 12/31/1969
Indiana University Medical Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Depot Naltrexone Treatment of Opioid Dependent Parolees
Depot Naltrexone Treatment of Opioid Dependent Parolees
Status: Enrolling
Updated:  12/31/1969
414
mi
from 43215
Philadelphia, PA
Depot Naltrexone Treatment of Opioid Dependent Parolees
Depot Naltrexone Treatment of Opioid Dependent Parolees
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Birmingham, AL
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 198
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Birmingham, AL
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 931
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Huntsville, AL
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 286
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Montgomery, AL
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 032
mi
from 43215
Montgomery, AL
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Scottsdale, AZ
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 253
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Tucson, AZ
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 307
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Tucson, AZ
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 377
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
North Little Rock, AR
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 574
mi
from 43215
North Little Rock, AR
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Beverly Hills, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 059
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Encinitas, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 411
mi
from 43215
Encinitas, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Fountain Valley, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 021
mi
from 43215
Fountain Valley, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
La Jolla, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 261
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Los Angeles, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 220
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Oceanside, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 728
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Palm Springs, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 571
mi
from 43215
Palm Springs, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
San Carlos, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 485
mi
from 43215
San Carlos, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Torrance, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 027
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Van Nuys, CA
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 580
mi
from 43215
Van Nuys, CA
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Boulder, CO
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 946
mi
from 43215
Boulder, CO
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Lonetree, CO
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 491
mi
from 43215
Lonetree, CO
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Hamden, CT
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 087
mi
from 43215
Hamden, CT
Click here to add this to my saved trials
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Hartford, CT
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
C87075 077
mi
from 43215
Hartford, CT
Click here to add this to my saved trials